Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02564900 · ClinicalTrials.gov registry record · Phase 1

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by Daiichi Sankyo Co..

Completed
Registry status
Phase 1
Development phase
292
Enrollment target
14
Study locations

NCT02564900 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Daiichi Sankyo Co.. The registered enrollment target is 292 participants, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (48% higher). The trial reports 14 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02564900, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Daiichi Sankyo Co..

COMPLETED
Registry status
Phase 1
Development phase
292 participants
Enrollment target
14
Study locations

Study Summary

This is an open-label, two-part, multicenter study to evaluate the safety and tolerability of DS-8201a in participants with advanced solid malignant tumors.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG DS-8201a (DP1)
  • DRUG DS-8201a (DP2)
  • DRUG DS-8201a (DP)

Study Locations (14)

Other

  • Aichi Cancer Center Hospital - Aichi
  • National Cancer Center Hospital East - Chiba
  • Social Medical Corporation Hakuaikai Sagara Hospital - Kagoshima
  • Kindai University Hospital - Osaka
  • National Cancer Center Hospital - Tokyo
  • The Cancer Institute Hospital of Japanese Foundation For Cancer Research - Tokyo

California

  • Sharp Memorial Hospital - San Diego

Florida

  • Mayo Clinic - Jacksonville

Kentucky

  • University of Louisville - Louisville

Massachusetts

  • Dana Farber Cancer Institute - Boston

Missouri

  • Washington University School of Medicine - St Louis

New York

  • Memorial Sloan-Kettering Cancer Center - New York

Ohio

  • UC Health Clinical Trials Office - Cincinnati

Trial Details

FieldValue
Enrollment Target 292 participants
Start Date 2015-09-01
Est. Completion 2023-12-22
Phase Phase 1

Sponsor

Daiichi Sankyo Co.

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02564900

The ClinicalTrials.gov registry entry for NCT02564900 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (48% higher). The listed sponsor is Daiichi Sankyo Co., which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which DS-8201a (DP1) is the first listed.

NCT02564900 reports 14 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT02564900 about?

NCT02564900 is a clinical study titled "Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors". This is an open-label, two-part, multicenter study to evaluate the safety and tolerability of DS-8201a in participants with advanced solid malignant tumors.

What is the current status of trial NCT02564900?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 292 participants. The study started on 2015-09-01. Estimated completion is 2023-12-22.

What conditions does trial NCT02564900 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT02564900?

The interventions under investigation include: DS-8201a (DP1) (DRUG), DS-8201a (DP2) (DRUG), DS-8201a (DP) (DRUG).

Who is sponsoring clinical trial NCT02564900?

This trial is sponsored by Daiichi Sankyo Co., which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02564900 being conducted?

This trial has 14 study locations across California, Florida, Kentucky, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.